Apogee Therapeutics to Participate in Upcoming June Investor Conferences

Rhea-AI Summary

Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotech company focused on developing biologics for atopic dermatitis, COPD, asthma, and other inflammatory and immunology conditions, announced its participation in two upcoming investor conferences. The Jefferies Global Healthcare Conference will take place on June 6, 2024, at 8:30 a.m. ET, followed by the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 11:20 a.m. ET. Live and archived webcasts of these events will be accessible through the company's website.

Positive

• Participation in high-profile investor conferences may increase visibility and attract potential investors.
• Opportunities to present at Jefferies and Goldman Sachs conferences signal industry recognition and credibility.

Negative

• The press release lacks specific updates on financial performance or clinical trial progress, which may leave investors seeking more substantive information.
• No new product developments or partnerships were announced, which could mean immediate business growth.

SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that members of management will participate at the following upcoming investor conferences:

Jefferies Global Healthcare Conference
Date: Thursday, June 6, 2024
Time: 8:30 a.m. ET

Goldman Sachs 45^th Annual Global Healthcare Conference
Date: Monday, June 10, 2024
Time: 11:20 a.m. ET

A live and archived webcast of the fireside chat and presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee Therapeutics

Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB
dan@1abmedia.com

FAQ

What conferences will Apogee Therapeutics participate in June 2024?

Apogee Therapeutics will participate in the Jefferies Global Healthcare Conference on June 6, 2024, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024.

When is the Jefferies Global Healthcare Conference Apogee Therapeutics will attend?

The Jefferies Global Healthcare Conference is scheduled for June 6, 2024, at 8:30 a.m. ET.

What is the date and time for Apogee Therapeutics’ presentation at the Goldman Sachs Global Healthcare Conference?

Apogee Therapeutics will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 11:20 a.m. ET.

Where can I watch the live webcast of Apogee Therapeutics’ investor conference presentations?

The live and archived webcasts of Apogee Therapeutics’ presentations will be available on the News & Events page in the Investors section of the company's website.